Mylan CEO to Be Grilled by Congress Over EpiPen Price Surge
- House Oversight hearing scheduled for Sept. 21 in Washington
- FDA official says agency aware cost is excessive for some
Heather Bresch, chief executive officer of drugmaker Mylan Inc., speaks during an interview in New York on Jan. 8, 2015.
Photographer: Victor J. Blue/BloombergThis article is for subscribers only.
Mylan NV’s chief executive officer will make a very different trip to Washington next week, years after she helped successfully lobby for expanded use of the company’s EpiPen allergy shot.
CEO Heather Bresch is scheduled to appear before the U.S. House Committee on Oversight and Government Reform on Sept. 21, when members will question her about how the company raised the price of the life-saving injection to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007.